We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.035 | -0.68% | 5.095 | 4.70 | 5.49 | 5.00 | 4.70 | 4.70 | 180,475 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.54 | 9.46M |
TIDMSNG
RNS Number : 2615C
Synairgen plc
15 October 2020
Synairgen plc
("Synairgen" or the "Company")
Exercise of Options and Total Voting Rights
Southampton, UK - 15 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that the Company has applied for a total of 177,300 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be issued and allotted pursuant to the exercise of options by Jody Brookes, PDMR, and certain other employees of the Company.
Of these new Ordinary Shares, 141,702 were exercised at a price of 1 pence by Jody Brookes and subsequent to this, the Company was notified on 15 October that on that same day, Jody Brookes sold the 141,702 Ordinary Shares at a price of 198.327 pence per Ordinary Share.
As a result of the exercise of options, application has been made for the 177,300 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on or around 21 October 2020.
The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 165,088,214 Ordinary Shares. Accordingly, the figure of 165,088,214 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)
finnCap - Nominated Adviser and Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane / Sunila de Silva (ECM)
Numis - Joint Broker +44 (0) 20 7260 1000
James Black / Freddie Barnfield / Duncan Monteith
Consilium Strategic Communications - Financial Media and Investor +44 (0) 20 3709 5700
Relations Adviser
Mary-Jane Elliott / Sue Stuart / Olivia Manser
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') a) Name Jody Brookes 2. Reason for notification a) Position / status Head of Clinical Operations, PDMR of the Company b) Initial notification Initial Notification / amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Synairgen plc b) LEI 213800IMMTOPPDF8HD24 4. Details of the transaction(s): a) Description of the financial O ptions over o rdinary shares of 1p each instrument Identification code GB00B0381Z20 b) Nature of the transaction Exercise of options over Ordinary Shares; and Sale of Ordinary Shares of 1p each c) Price(s) and volume(s) Price Volume Exercise of Options 1p 141,702 --------- -------- Sale of Ordinary Shares 198.327p 141,702 --------- -------- d) Aggregated information n/a Aggregated volume Price e) Date of the transaction 15 October 2020 f) Place of the transaction London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBLBDGGXBDGGU
(END) Dow Jones Newswires
October 15, 2020 12:35 ET (16:35 GMT)
1 Year Synairgen Chart |
1 Month Synairgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions